FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050795811> ?p ?o ?g. }

• W2050795811 endingPage "787" @default.
• W2050795811 startingPage "780" @default.
• W2050795811 abstract "Objective To analyze the expression of the antiapoptotic gene bcl-xL in human pancreatic cancer and to correlate the results with clinical patient parameters. Summary Background Data Bcl-xL belongs to the bcl-2-related gene family and acts as a broad antiapoptotic factor to extend both normal and tumor cell survival. Recent findings indicate that tumor cell death induced by chemotherapy and radiotherapy is mediated by the activation of apoptosis. The fact that pancreatic cancer has an extremely malignant potential and that it is resistant to most anticancer treatment modalities suggests that mechanisms are activated that increase the viability of pancreatic cancer cells. Methods Seventy-four pancreatic cancer tissue samples were obtained from 32 female and 42 male patients undergoing surgery for exocrine pancreatic cancer. Normal human pancreatic tissue samples were available from 11 organ donors and 4 patients without pancreatic disease. The levels of bcl-xL mRNA expression were analyzed by Northern blot analysis. The exact site of bcl-xL mRNA transcription was determined by nonradioactive in situ hybridization. In addition, immunohistochemistry using specific polyclonal antibodies was used to localize the protein. Results Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-xL mRNA was markedly overexpressed in 54% of the pancreatic cancer samples. Densitometric analysis revealed that pancreatic adenocarcinomas exhibited a mean 3.4-fold increase (p < 0.01) in bcl-xL mRNA levels in comparison with normal controls. With in situ hybridization, bcl-xL mRNA was found to be highly expressed in the cancer cells of tumor samples that exhibited increased mRNA expression by Northern blot analysis. Immunohistochemical analysis revealed bcl-x immunostaining in 88% of the cancer samples. Correlation of the molecular data with clinical patient parameters revealed that patients whose tumors exhibited no, faint, or weak bcl-xL expression lived significantly longer after tumor resection (median 12 months) than patients whose tumors exhibited moderate bcl-xL mRNA expression (median 5 months) (p < 0.05). However, 5 patients whose tumors exhibited intense bcl-xL mRNA expression tended to live longer (median 14 months). Conclusion Enhanced expression of the antiapoptotic gene bcl-xL in pancreatic cancer and its association with shorter patient survival suggests that this factor may enhance the viability of pancreatic cancer cells in vivo. Inhibition of apoptotic pathways might be one of the reasons why pancreatic cancer shows only limited sensitivity to anticancer treatment." @default.
• W2050795811 created "2016-06-24" @default.
• W2050795811 creator A5008215786 @default.
• W2050795811 creator A5009418325 @default.
• W2050795811 creator A5011216679 @default.
• W2050795811 creator A5023256445 @default.
• W2050795811 creator A5036032282 @default.
• W2050795811 creator A5047474769 @default.
• W2050795811 creator A5048928035 @default.
• W2050795811 creator A5089608755 @default.
• W2050795811 date "1998-12-01" @default.
• W2050795811 modified "2023-10-16" @default.
• W2050795811 title "Moderate Activation of the Apoptosis Inhibitor bcl-xL Worsens the Prognosis in Pancreatic Cancer" @default.
• W2050795811 cites W1531587291 @default.
• W2050795811 cites W1568678893 @default.
• W2050795811 cites W1591166893 @default.
• W2050795811 cites W1638076008 @default.
• W2050795811 cites W1784863686 @default.
• W2050795811 cites W1876786158 @default.
• W2050795811 cites W1966059563 @default.
• W2050795811 cites W1966246019 @default.
• W2050795811 cites W1966465634 @default.
• W2050795811 cites W1971234510 @default.
• W2050795811 cites W1976128207 @default.
• W2050795811 cites W1978333973 @default.
• W2050795811 cites W1994068418 @default.
• W2050795811 cites W2005277488 @default.
• W2050795811 cites W2008279940 @default.
• W2050795811 cites W2011816149 @default.
• W2050795811 cites W2024429555 @default.
• W2050795811 cites W2024582476 @default.
• W2050795811 cites W2032592355 @default.
• W2050795811 cites W2040154556 @default.
• W2050795811 cites W2043066069 @default.
• W2050795811 cites W2044313019 @default.
• W2050795811 cites W2046614423 @default.
• W2050795811 cites W2057713336 @default.
• W2050795811 cites W2058591356 @default.
• W2050795811 cites W2063176993 @default.
• W2050795811 cites W2068040848 @default.
• W2050795811 cites W2080505947 @default.
• W2050795811 cites W2092520899 @default.
• W2050795811 cites W2099963806 @default.
• W2050795811 cites W2128077493 @default.
• W2050795811 cites W2134230584 @default.
• W2050795811 cites W2134979684 @default.
• W2050795811 cites W2135753091 @default.
• W2050795811 cites W2155706280 @default.
• W2050795811 cites W2169495754 @default.
• W2050795811 cites W2171725581 @default.
• W2050795811 cites W2172072395 @default.
• W2050795811 cites W2233325915 @default.
• W2050795811 cites W2413881990 @default.
• W2050795811 cites W2414261930 @default.
• W2050795811 cites W2473830304 @default.
• W2050795811 cites W26755955 @default.
• W2050795811 cites W335061608 @default.
• W2050795811 cites W418633995 @default.
• W2050795811 cites W4233484287 @default.
• W2050795811 cites W4294112996 @default.
• W2050795811 cites W43675158 @default.
• W2050795811 doi "https://doi.org/10.1097/00000658-199812000-00009" @default.
• W2050795811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1191596" @default.
• W2050795811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9860477" @default.
• W2050795811 hasPublicationYear "1998" @default.
• W2050795811 type Work @default.
• W2050795811 sameAs 2050795811 @default.
• W2050795811 citedByCount "109" @default.
• W2050795811 countsByYear W20507958112012 @default.
• W2050795811 countsByYear W20507958112013 @default.
• W2050795811 countsByYear W20507958112014 @default.
• W2050795811 countsByYear W20507958112015 @default.
• W2050795811 countsByYear W20507958112016 @default.
• W2050795811 countsByYear W20507958112017 @default.
• W2050795811 countsByYear W20507958112018 @default.
• W2050795811 countsByYear W20507958112019 @default.
• W2050795811 countsByYear W20507958112020 @default.
• W2050795811 countsByYear W20507958112021 @default.
• W2050795811 countsByYear W20507958112022 @default.
• W2050795811 crossrefType "journal-article" @default.
• W2050795811 hasAuthorship W2050795811A5008215786 @default.
• W2050795811 hasAuthorship W2050795811A5009418325 @default.
• W2050795811 hasAuthorship W2050795811A5011216679 @default.
• W2050795811 hasAuthorship W2050795811A5023256445 @default.
• W2050795811 hasAuthorship W2050795811A5036032282 @default.
• W2050795811 hasAuthorship W2050795811A5047474769 @default.
• W2050795811 hasAuthorship W2050795811A5048928035 @default.
• W2050795811 hasAuthorship W2050795811A5089608755 @default.
• W2050795811 hasBestOaLocation W20507958112 @default.
• W2050795811 hasConcept C104317684 @default.
• W2050795811 hasConcept C105580179 @default.
• W2050795811 hasConcept C121608353 @default.
• W2050795811 hasConcept C126322002 @default.
• W2050795811 hasConcept C142724271 @default.
• W2050795811 hasConcept C144369459 @default.
• W2050795811 hasConcept C177707886 @default.
• W2050795811 hasConcept C190283241 @default.
• W2050795811 hasConcept C204232928 @default.

• next